N-palmitoyl-ethanolamine: Biochemistry and new therapeutic opportunities

Biochimie

Volumn 92, Issue 6, 2010, Pages 724-727

  Petrosino, Stefania ^a   Iuvone, Teresa ^b   Di Marzo, Vincenzo ^a  

^a CNR   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Allergy; FAAH; Inflammation; N Acylethanolamines; NAAA; Pain; PEA

Indexed keywords

AMIDASE; ANANDAMIDE; CYCLOHEXYL HEXADECANOATE; CYCLOPENTYL HEXADECANOATE; ENZYME INHIBITOR; HEXADECYL PROPRIONATE; N (3 HYDROXY PROPIONYL)PENTADECANAMIDE; N ACYLETHANOLAMINE HYDROLYZING ACID AMIDASE; N ACYLETHANOLAMINE HYDROLYZING ACID AMIDASE INHIBITOR; N OLEOYLETHANOLAMINE; N PENTADECYLBENZAMIDE; N PENTADECYLCYCLOHEXANECARBOXAMIDE; NORMAST; PALMIDROL; PELVILEN; UNCLASSIFIED DRUG;

ANTIANGIOGENIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTINOCICEPTION; BIOCHEMISTRY; CATABOLISM; DRUG MECHANISM; DRUG STRUCTURE; ENZYME INHIBITION; GRANULOMA; HUMAN; INFLAMMATION; MYELITIS; NEUROPATHY; NONHUMAN; REVIEW; SKIN ALLERGY; SPINAL CORD INJURY;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ETHANOLAMINES; HUMANS; INFLAMMATION; PALMITIC ACIDS;

MAMMALIA;

EID: 77953291080     PISSN: 03009084     EISSN: 61831638     Source Type: Journal    
DOI: 10.1016/j.biochi.2010.01.006     Document Type: Review

References (42)

1. Masek K., Perlík F., Klíma J., Kahlich R. Prophylactic efficacy of N-2-hydroxyethyl palmitamide (impulsin) in acute respiratory tract infections. Eur. J. Clin. Pharmacol. 1974, 7:415-419.
2. Lo Verme J., Fu J., Astarita G., et al. The nuclear receptor peroxisome proliferator-activated receptor-alpha mediates the anti-inflammatory actions of Palmitoylethanolamide. Mol. Pharmacol. 2005, 67:15-19.
3. Re G., Barbero R., Miolo A., Di Marzo V. Palmitoylethanolamide, endocannabinoids and related cannabimimetic compounds in protection against tissue inflammation and pain: potential use in companion animals. Vet. J. 2007, 173:21-30.
4. Okamoto Y., Morishita J., Tsuboi K., Tonai T., Ueda N. Molecular characterization of a phospholipase D generating anandamide and its congeners. J. Biol. Chem. 2004, 279:5298-5305.
5. Wang J., Okamoto Y., Morishita J., Tsuboi K., Miyatake A., Ueda N. Functional analysis of the purified anandamide-generating phospholipase D as a member of the metallo-beta-lactamase family. J. Biol. Chem. 2006, 281:12325-12335.
6. Petrosino S., Ligresti A., Di Marzo V. Endocannabinoid chemical biology: a tool for the development of novel therapies. Curr. Opin. Chem. Biol. 2009, 13:309-320.
7. Sun Y.X., Tsuboi K., Okamoto Y., et al. Biosynthesis of anandamide and N-palmitoyl-ethanolamine by sequential actions of phospholipase A2 and lysophospholipase D. Biochem. J. 2004, 380:749-756.
8. Simon G.M., Cravatt B.F. Endocannabinoid biosynthesis proceeding through glycerophospho-N-acyl ethanolamine and a role for alpha/beta-hydrolase 4 in this pathway. J. Biol. Chem. 2006, 281:26465-26472.
9. Liu J., Wang L., Harvey-White J., et al. A biosynthetic pathway for anandamide. Proc. Natl. Acad. Sci. U S A 2006, 103:13345-13350.
10. Liu J., Wang L., Harvey-White J., et al. Multiple pathways involved in the biosynthesis of anandamide. Neuropharmacology 2008, 54:1-7.
11. Cravatt B.F., Giang D.K., Mayfield S.P., Boger D.L., Lerner R.A., Gilula N.B. Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides. Nature 1996, 384:83-87.
12. Giang D.K., Cravatt B.F. Molecular characterization of human and mouse fatty acid amide hydrolases. Proc. Natl. Acad. Sci. U S A 1997, 94:2238-2242.
13. Ueda N., Yamanaka K., Yamamoto S. Purification and characterization of an acid amidase selective for N-palmitoyl-ethanolamine, a putative endogenous anti-inflammatory substance. J. Biol. Chem. 2001, 276:35552-35557.
14. Tsuboi K., Sun Y.X., Okamoto Y., Araki N., Tonai T., Ueda N. Molecular characterization of N-acyl-ethanolamine-hydrolyzing acid amidase, a novel member of the choloylglycine hydrolase family with structural and functional similarity to acid ceramidase. J. Biol. Chem. 2005, 280:11082-11092.
15. Tsuboi K., Zhao L.Y., Okamoto Y., et al. Predominant expression of lysosomal N-acyl-ethanolamine-hydrolyzing acid amidase in macrophages revealed by immunochemical studies. Biochim. Biophys. Acta 2007, 1771:623-632.
16. Zhao L.Y., Tsuboi K., Okamoto Y., Nagahata S., Ueda N. Proteolytic activation and glycosylation of N-acylethanolamine-hydrolyzing acid amidase, a lysosomal enzyme involved in the endocannabinoid metabolism. Biochim. Biophys. Acta 2007, 1771:1397-1405.
17. Aloe L., Leon A., Levi-Montalcini R. A proposed autacoid mechanism controlling mastocyte behaviour. Agents Actions 1993, 39:145-147.
18. Conti S., Costa B., Colleoni M., Parolaro D., Giagnoni G. Anti-inflammatory action of endocannabinoid palmitoylethanolamide and the synthetic cannabinoid nabilone in a model of acute inflammation in the rat. Br. J. Pharmacol. 2002, 135:181-187.
19. Ben-Shabat S., Fride E., Sheskin T., et al. An entourage effect: inactive endogenous fatty acid glycerol esters enhance 2-arachidonoyl-glycerol cannabinoid activity. Eur. J. Pharmacol. 1998, 353:23-31.
20. Lambert D.M., Di Marzo V. The palmitoylethanolamide and oleamide enigmas: are these two fatty acid amides cannabimimetic?. Curr. Med. Chem. 1999, 9:757-773.
21. Di Marzo V., Melck D., Orlando P., et al. Palmitoylethanolamide inhibits the expression of fatty acid amide hydrolase and enhances the anti-proliferative effect of anandamide in human breast cancer cells. Biochem. J. 2001, 358:249-255.
22. De Petrocellis L., Davis J.B., Di Marzo V. Palmitoylethanolamide enhances anandamide stimulation of human vanilloid VR1 receptors. FEBS Lett. 2001, 506:253-256.
23. Smart D., Jonsson K.O., Vandevoorde S., Lambert D.M., Fowler C.J. 'Entourage' effects of N-acyl ethanolamines at human vanilloid receptors. Comparison of effects upon anandamide-induced vanilloid receptor activation and upon anandamide metabolism. Br. J. Pharmacol. 2002, 136:452-458.
24. Ho W.S., Barrett D.A., Randall M.D. 'Entourage' effects of N-palmitoylethanolamide and N-oleoylethanolamide on vasorelaxation to anandamide occur through TRPV1 receptors. Br. J. Pharmacol. 2008, 155:837-846.
25. Costa B., Comelli F., Bettoni I., Colleoni M., Giagnoni G. The endogenous fatty acid amide, palmitoylethanolamide, has anti-allodynic and anti-hyperalgesic effects in a murine model of neuropathic pain: involvement of CB(1), TRPV1 and PPAR gamma receptors and neurotrophic factors. Pain 2008, 139:541-550.
26. Calignano A., La Rana G., Giuffrida A., Piomelli D. Control of pain initiation by endogenous cannabinoids. Nature 1998, 394:277-281.
27. Calignano A., La Rana G., Piomelli D. Antinociceptive activity of the endogenous fatty acid amide, palmitylethanolamide. Eur. J. Pharmacol. 2001, 419:191-198.
28. Ryberg E., Larsson N., Sjögren S., et al. The orphan receptor GPR55 is a novel cannabinoid receptor. Br. J. Pharmacol. 2007, 152:1092-1101.
29. Kapur A., Zhao P., Sharir H., et al. Atypical responsiveness of the orphan receptor GPR55 to cannabinoid ligands. J. Biol. Chem. 2009, 284:29817-29827.
30. Darmani N.A., Izzo A.A., Degenhardt B., et al. Involvement of the cannabimimetic compound, N-palmitoyl-ethanolamine, in inflammatory and neuropathic conditions: review of the available pre-clinical data, and first human studies. Neuropharmacology 2005, 48:1154-1163.
31. Vandevoorde S., Tsuboi K., Ueda N., Jonsson K.O., Fowler C.J., Lambert D.M. Esters, retroesters, and a retroamide of palmitic acid: pool for the first selective inhibitors of N-palmitoyl-ethanolamine-selective acid amidase. J. Med. Chem. 2003, 46:4373-4376.
32. Tsuboi K., Hilligsmann C., Vandevoorde S., Lambert D.M., Ueda N. N-cyclohexanecarbonylpentadecylamine: a selective inhibitor of the acid amidase hydrolyzing N-acyl-ethanolamines, as a tool to distinguish acid amidase from fatty acid amide hydrolase. Biochem. J. 2004, 379:99-106.
33. Saturnino C., Petrosino S., Ligresti A., et al. Synthesis and biological evaluation of new analogues of palmitic acid as inhibitors of N-acyl-ethanolamine-hydrolyzing acid amidase. Bioorg. Med. Chem. Lett. 2010, 20:1210-1213.
34. Ueda N., Tsuboi K., Lambert D.M. A second N-acylethanolamine hydrolase in mammalian tissues. Neuropharmacology 2005, 48:1079-1085.
35. De Filippis D., D'Amico A., Cipriano M., et al. Levels of endocannabinoids and palmitoylethanolamide and their pharmacological manipulation in chronic granulomatous inflammation in rats. Pharmacol. Res. 2009, [Epub ahead of print].
36. Solorzano C., Zhu C., Battista N., et al. Selective N-acylethanolamine-hydrolyzing acid amidase inhibition reveals a key role for endogenous palmitoylethanolamide in inflammation. Proc. Natl. Acad. Sci. U S A 2009, 106:20966-20971.
37. Genovese T., Esposito E., Mazzon E., et al. Effects of palmitoylethanolamide on signaling pathways implicated in the development of spinal cord injury. J. Pharmacol. Exp. Ther. 2008, 326:12-23.
38. D'Agostino G., La Rana G., Russo R., et al. Central administration of palmitoylethanolamide reduces hyperalgesia in mice via inhibition of NF-kappaB nuclear signalling in dorsal root ganglia. Eur. J. Pharmacol. 2009, 613:54-59.
39. Loría F., Petrosino S., Mestre L., et al. Study of the regulation of the endocannabinoid system in a virus model of multiple sclerosis reveals a therapeutic effect of Palmitoylethanolamide. Eur. J. Neurosci. 2008, 28:633-641.
40. García Mdel C., Adler-Graschinsky E., Celuch S.M. Enhancement of the hypotensive effects of intrathecally injected endocannabinoids by the entourage compound Palmitoylethanolamide. Eur. J. Pharmacol. 2009, 610:75-80.
41. P. Garg, R.S. Duncan, S. Kaja, P. Koulen, Intracellular mechanisms of N-acylethanolamine-mediated neuroprotection in a rat model of stroke. Neuroscience 2009 Dec 3 [Epub ahead of print].
42. Petrosino S., Cristino L., Karsak M., et al. Protective role of palmitoylethanolamide in contact allergic dermatitis. Allergy 2009, [Epub ahead of print].